Differential antiatherogenic effects of PPARα versus PPARγ agonists -: Should we be surprised?

被引：2
作者：
Camejo, G [1 ]
机构：
[1] AstraZeneca, Discovery, S-43183 Molndal, Sweden
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2005年 / 25卷 / 09期
关键词：
D O I：
10.1161/01.ATV.0000181034.54148.8d
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1763 / 1764
页数：2
相关论文
共 14 条
[1]   Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice - Pleiotropic effects on CD36 expression and HDL [J].
Chen, Z ;
Ishibashi, S ;
Perrey, S ;
Osuga, J ;
Gotoda, T ;
Kitamine, T ;
Tamura, Y ;
Okazaki, H ;
Yahagi, N ;
Iizuka, Y ;
Shionoiri, F ;
Ohashi, K ;
Harada, K ;
Shimano, H ;
Nagai, R ;
Yamada, N .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) :372-377
[2]   Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice [J].
Collins, AR ;
Meehan, WP ;
Kintscher, U ;
Jackson, S ;
Wakino, S ;
Noh, G ;
Palinski, W ;
Hsueh, WA ;
Law, RE .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) :365-371
[3]   The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. [J].
Fazio S. ;
Linton M.F. .
Current Atherosclerosis Reports, 2004, 6 (2) :148-157
[4]   Nuclear receptors and the control of metabolism [J].
Francis, GA ;
Fayard, E ;
Picard, F ;
Auwerx, J .
ANNUAL REVIEW OF PHYSIOLOGY, 2003, 65 :261-311
[5]   PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia [J].
Hennuyer, N ;
Tailleux, A ;
Torpier, G ;
Mezdour, H ;
Fruchart, JC ;
Staels, B ;
Fiévet, C .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (09) :1897-1902
[6]   Roles of PPARs in health and disease [J].
Kersten, S ;
Desvergne, B ;
Wahli, W .
NATURE, 2000, 405 (6785) :421-424
[7]   Apo E structure determines VLDL clearance and atherosclerosis risk in mice [J].
Knouff, C ;
Hinsdale, ME ;
Mezdour, H ;
Altenburg, MK ;
Watanabe, M ;
Quarfordt, SH ;
Sullivan, PM ;
Maeda, N .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (11) :1579-1586
[8]   Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus -: Results from a controlled randomized study [J].
Langenfeld, MR ;
Forst, T ;
Hohberg, C ;
Kann, P ;
Lübben, G ;
Konrad, T ;
Füllert, SD ;
Sachara, C ;
Pfützner, A .
CIRCULATION, 2005, 111 (19) :2525-2531
[9]   Peroxisome proliferator-activate inhibit development of atherosclerosis in LDL receptor-deficient mice [J].
Li, AC ;
Brown, KK ;
Silvestre, MJ ;
Willson, TM ;
Palinski, W ;
Glass, CK .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (04) :523-531
[10]   Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and β [J].
Li, AC ;
Binder, CJ ;
Gutierrez, A ;
Brown, KK ;
Plotkin, CR ;
Pattison, JW ;
Valledor, AF ;
Davis, RA ;
Willson, TM ;
Witztum, JL ;
Palinski, W ;
Glass, CK .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (11) :1564-1576
12